Fox Chase Cancer Center

Institute for Cancer Research

Nexuspharma, Inc.

Georgetown University

Igor Astsaturov

Ilya G Serebriiskii

Erica A Golemis

Louis M Weiner

Vladimir Khazak

Andrew Godwin

Ilya Serebriiski

Vladimir Ratushny

Compositions and methods for the treatment and diagnosis of cancer are disclosed.

EGFR/NEDD9/TGF-&#x3b2; interactome and methods of use thereof for the identification of agents having efficacy in the treatment of hyperproliferative disorders

Systems and methods for determining whether a cancer patient may respond to inhibition of RNA polymerase II as a treatment for the patient are provided. Inhibition of RNA polymerase II may be by way of chemotherapy with an agent such as triptolide, an analog of triptolide, or a prodrug form of triptolide. The cancer patient may be a pancreatic cancer patient, an ovarian cancer patient, a gastric cancer patient, or an esophageal cancer patient. The patient may have any cancer in which c-Myc is over-expressed or over-amplified.

C-Myc as a biomarker for tumor sensitivity to treatment with RNA polymerase II inhibition

Method of treating MYC-amplified tumors with RNA-polymerase II inhibitors

Compositions which act synergistically to inhibit the growth of cancer cells and methods of use thereof are disclosed.

Combination therapy based on SRC and aurora kinase inhibition for the treatment of cancer

Growing community of inventors

Philadelphia, PA, United States of America

Igor Astsaturov